"10.1371_journal.pone.0052526","plos one","2013-02-05T00:00:00Z","Pamela J Hodul; Yanbin Dong; Kazim Husain; Jose M Pimiento; Jiandong Chen; Anying Zhang; Rony Francois; Warren J Pledger; Domenico Coppola; Said M Sebti; Dung-Tsa Chen; Mokenge P Malafa","Department of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States of America; Department of Molecular Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States of America; Department of Pathology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States of America; Department of Drug Discovery, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States of America; Biostatistics Core, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States of America; School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu, People's Republic of China; College of Medicine, University of Florida, Gainesville, Florida, United States of America","Conceived and designed the experiments: PJH YD KH JMP JC AZ RF WJP DC SMS DTC MPM. Performed the experiments: PJH YD KH AZ RF MPM. Analyzed the data: PJH JMP DC SMS DTC MPM. Contributed reagents/materials/analysis tools: JC WJP MPM. Wrote the paper: PJH YD KH JMP JC AZ RF WJP DC SMS DTC MPM.","This study involves intellectual property in which M. Malafa and S. Sebti are named as inventors. Drs. Malafa and Sebti and the Moffitt Cancer Center are entitled to receive licensing revenue from the exploitation of such intellectual property. A United States patent application was filed on June 26, 2007, having the title \"Delta-Tocotrienol Treatment and Prevention of Pancreatic Cancer\" (OTML docket number 06A069). The intellectual property included in the patent application has been licensed to BioGene Life Science, a Singapore based company. This license agreement grants BioGene Life Science rights to Dr. Malafa's discovery. BioGene Life Science is a wholly owned subsidiary of Davos Life Science. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.","2013","02","Pamela J Hodul","PJH",12,TRUE,12,6,6,12,TRUE,TRUE,FALSE,0,NA,FALSE
